CClinicalTrials.gg
Not yet recruitingNCT07667881CANCER PATIENTUpdated Jun 25, 2026

OUTPATIENT CANCER PATIENTS: THE RELATIONSHIP BETWEEN INFORMATION OVERLOAD, SYMPTOM SEVERITY, AND EMPOWERMENT LEVEL

An observational study in Oncologic Disease, sponsored by University of Yalova. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by University of Yalova · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

Examining the relationship between information load, symptom severity, and empowerment level in outpatient cancer patients is of great importance for developing holistic care plans tailored to the individual needs of patients and for planning supportive interventions in oncology nursing.

02

Conditions studied

  • Oncologic Disease

Keywords

  • cancer, information overload, symptom management, patient empowerment, nursing
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients over 18 years of age receiving outpatient chemotherapy treatment

Eligibility criteria

Inclusion Criteria: Eligibility criteria include having a clinical diagnosis of cancer, having received at least one course of outpatient chemotherapy, and being 18 years of age or older.

-

Exclusion Criteria: The criteria for eligibility include having a severe mental disorder that could affect the patient's perception and responses, it being the first day of treatment, and the patient being under 18 years of age.

-

04

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
300 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes
05

What researchers measure

Primary outcomes

  1. Relationship Between Information Burden, Symptom Management, and Empowerment Levels in Patients Receiving Outpatient Chemotherapy

    Evaluated via Cancer Patient Empowerment Scale (40 items, 5-point Likert). Subscales: Personal Power, Social Support, Healthcare, Community. Total score: 40-200. Higher scores indicate higher patient empowerment. Measured via Cancer Information Overload Scale (8 items, 4-point Likert). Total score: 8-32. Higher scores indicate higher cognitive burden. Evaluated via Memorial Symptom Assessment Scale (32 symptoms; GDI, Phys, Psych subscales). Total score (average): 0-4. Higher scores reflect higher symptom distress.

    Time frame: 01.07.2026-01.20.2026

  2. Information burden, symptom severity, and reinforcement level in outpatient chemotherapy patients

    Evaluated via Cancer Patient Empowerment Scale (40 items, 5-point Likert). Subscales: Personal Power, Social Support, Healthcare, Community. Total score: 40-200. Higher scores indicate higher patient empowerment. Measured via Cancer Information Overload Scale (8 items, 4-point Likert). Total score: 8-32. Higher scores indicate higher cognitive burden. Evaluated via Memorial Symptom Assessment Scale (32 symptoms; GDI, Phys, Psych subscales). Total score (average): 0-4. Higher scores reflect higher symptom distress.

    Time frame: 01.07.2026--01.10.2026

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Yilmaz Karabulutlu E, Bahcecioglu Turan G, Karaman S. Turkish Validity and Reliability Study of Cancer Empowerment Scale. Psychiatr Danub. 2021 Dec;33(Suppl 13):314-320. PubMed 35150501 ↗
  • Yildirim Y, Tokem Y, Bozkurt N, Fadiloglu C, Uyar M, Uslu R. Reliability and validity of the Turkish version of the Memorial Symptom Assessment Scale in cancer patients. Asian Pac J Cancer Prev. 2011;12(12):3389-96. PubMed 22471486 ↗
  • Tanrıkut, R., Koç, A. (2023). Son 10 yılda hemşirelik alanında semptom yönetimi konulu yüksek lisans ve doktora tezlerin retrospektif incelenmesi. Medical Research Reports, 6(3), 164-182
  • Sezgin, M. G., Bektaş, H. (2022). Multipl myelom hastalarında güncel tedavi önerileri ve semptom yönetimi. Ege Üniversitesi Hemşirelik Fakültesi Dergisi, 38(1), 49-59.
  • Seven M, AKYÜZ A, Sever N, Dinçer Ş (2013). Kanser tanısı alan hastaların yaşadığı fiziksel ve psikolojik semptomların belirlenmesi. TAF Prev Med Bull 12(3):219-224.
  • Pehlivan, Z., Gülhan Güner, S., Nural, N. (2022). Kanser hastalarında bir semptom konstipasyon: Literatür incelemesi. İzmir Kâtip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi, 7(1), 139-144.
  • Pekmezci, H., Genç Köse, B., Akbal, Y., Aşık Özdemir, V., Kefeli Çol, B. (2022). Kemoterapi alan kanser hastalarının semptom yönetiminde tamamlayıcı terapi kullanımları. Sağlık Akademisyenleri Dergisi, 9(3), 211-219.
  • Öztoprak, F. S., Ege, E. (2021). Kadın işçilerin kanser bilgi yükü ile sağlıklı yaşam biçimi davranışları ilişkisinin incelenmesi. Ege Üniversitesi Hemşirelik Fakültesi Dergisi, 37(2), 141-156.
  • Özmen, S., Kocakaya, K. (2024).Kanser Hastalarında Hasta Güçlendirmenin Yaşam Kalitesi Üzerindeki Etkisi. İnönü Üniversitesi Sağlık Hizmetleri Meslek Yüksek Okulu Dergisi, 12(1), 99-117.
  • Negussie F, Giru BW, Yusuf NT, Gela D. Psychological distress and associated factors among cancer patients in public hospitals, Addis Ababa, Ethiopia: a cross-sectional study. BMC Psychol. 2023 Feb 10;11(1):41. doi: 10.1186/s40359-023-01079-5. PubMed 36765415 ↗
  • National Cancer Institute-NCI. Erişim Linki: https://www.cancer.gov/search/results?swKeyword=oral+mucositis
  • Kalaycıoğlu, G. (2023). Kemoterapi alan hastaların öz bakım yönetimi ve hasta güçlendirme arasındaki ilişki [Yüksek lisans tezi, İstanbul Sabahattin Zaim Üniversitesi]. Lisansüstü Eğitim Enstitüsü
  • Kabak Solak T., Solak Ü., Avşar G. (2022). Kanserli bireylerde uyku kalitesini artırmaya yönelik yapılan hemşirelik girişimleri: Sistematik derleme. Güncel Hemşirelik Araştırmaları Dergisi, 2(1), 19-29.
  • İnci, F. H., Akgül Başkale, H., Serçekuş Ak, P. (2019). Kanser bilgi yükü ölçeği'nin Türkçeye uyarlanması, geçerlilik-güvenilirlik çalışması. Çukurova Medical Journal, 44(1), 127-135.
  • Güneş, D., Atalıkoğlu Başkan, S. (2024). Kemoterapi tedavisi alan hastaların yaşadığı semptomların öz bakım davranışlarına etkisi. Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi, 11(1), 70-76.
  • Erdoğan Yüce, G., Muz, G. (2020). Kanser hastalarında tedaviye bağlı bulantı ve kusmanın yönetimi. Nevşehir Bilim ve Tıp Dergisi, 9(2), 116-120.
  • Değer, M. S., Zoroğlu, G. (2021). Birinci basamak sağlık kuruluşuna başvuranlarda sağlık okuryazarlığı ile kanser bilgi yükü ilişkisi. Anadolu Kliniği Tıp Bilimleri Dergisi, 26(1), 108-117.
  • Bölükbaş Yurdoğlu, G., Kıymaç Sarı, M., & Durna, Z. (2024). Kemoterapi uygulanan kanser hastalarının gastrointestinal sistem semptomları ve hemşirelik yönetimi. Erciyes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi, 11(1), 56-62.
  • Akkuş, E. (2024). Kemoterapi alan hastalarda güçlendirmenin yaşanan semptomlara etkisi (Yüksek lisans tezi). İstanbul Sabahattin Zaim Üniversitesi, Lisansüstü Eğitim Enstitüsü, İstanbul
  • Akbulut, Ö. (2021). Çok değişkenli ve farklı ölçekli araştırmalarda örneklem büyüklüğünün tespiti. Journal of Animal Science and Products (JASP), 4(2), 199-215.
  • Adam R, Nair R, Duncan LF, Yeoh E, Chan J, Vilenskaya V, Gallacher KI. Treatment burden in individuals living with and beyond cancer: A systematic review of qualitative literature. PLoS One. 2023 May 25;18(5):e0286308. doi: 10.1371/journal.pone.0286308. eCollection 2023. PubMed 37228101 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared to protect participant confidentiality and privacy

08

Registry details

Key details

Study ID
NCT07667881
Lead sponsor
University of Yalova
Responsible party
Seyda Can (assoc prof, University of Yalova) — Principal investigator
First posted
Jun 25, 2026
Start date
Jul 2026 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jun 25, 2026

Study contacts

Şeyda CAN, assoc. prof.
Contact
seyda.can@yalova.edu.tr
+905366850312

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion